abrdn plc boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 843.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,641 shares of the medical research company's stock after buying an additional 55,104 shares during the period. abrdn plc's holdings in Exact Sciences were worth $3,464,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the company. Chicago Capital LLC lifted its holdings in Exact Sciences by 126.5% in the 4th quarter. Chicago Capital LLC now owns 10,080 shares of the medical research company's stock valued at $566,000 after purchasing an additional 5,629 shares in the last quarter. Chicago Partners Investment Group LLC lifted its stake in shares of Exact Sciences by 10.3% in the fourth quarter. Chicago Partners Investment Group LLC now owns 10,212 shares of the medical research company's stock worth $579,000 after buying an additional 951 shares in the last quarter. Gagnon Securities LLC boosted its position in Exact Sciences by 5.4% during the fourth quarter. Gagnon Securities LLC now owns 246,204 shares of the medical research company's stock worth $13,834,000 after acquiring an additional 12,621 shares during the last quarter. Baader Bank Aktiengesellschaft purchased a new stake in Exact Sciences during the 4th quarter valued at about $4,329,000. Finally, Swedbank AB raised its holdings in Exact Sciences by 76.1% in the 4th quarter. Swedbank AB now owns 30,848 shares of the medical research company's stock valued at $1,733,000 after acquiring an additional 13,333 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.
Exact Sciences Trading Up 0.5 %
Shares of EXAS stock traded up $0.25 on Thursday, hitting $50.59. The stock had a trading volume of 2,023,345 shares, compared to its average volume of 2,146,591. The company's 50 day moving average price is $56.42 and its 200-day moving average price is $60.06. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm has a market capitalization of $9.36 billion, a P/E ratio of -43.24 and a beta of 1.24.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on EXAS shares. Canaccord Genuity Group dropped their price target on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Craig Hallum dropped their target price on Exact Sciences from $82.00 to $65.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Jefferies Financial Group lifted their price target on Exact Sciences from $84.00 to $85.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Benchmark reaffirmed a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Finally, Evercore ISI dropped their price target on shares of Exact Sciences from $80.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $72.76.
View Our Latest Report on EXAS
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Stories
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
